Spanios Labs transforms precision oncology research by harnessing Patient-Derived Organoids (PDOs) and Tumoroids (PDTs) to accelerate drug development for rare cancers. Their COMPASS platform utilizes patient-specific 3D tumor models with intact tumor microenvironments (TME) to enable reproducible preclinical studies. By supporting any drug modality against solid cancer indications, Spanios helps scientists fast-track the search for novel cures. Serving drug developers and clinical oncologists, their efficacy-first model removes guesswork from therapeutic validation, aiming to bring hope to millions of patients through faster identification of effective treatments.